
Talk Is Cheap: Now Trump Must Deliver On His Healthcare Promises
President Donald Trump, accompanied by Health and Human Services Secretary Robert F. Kennedy Jr. ... More (R), holds up an executive order aimed at reducing the cost of prescription drugs and pharmaceuticals by 30% to 80% during an event in the Roosevelt Room of the White House on May 12, 2025, in Washington, D.C.
President Donald Trump has made big promises about fixing American healthcare. Now comes the moment that separates talk from action.
With the 2026 midterms fast approaching and congressional attention soon shifting to electoral strategy, the window for legislative results is closing quickly. This summer will determine whether the administration turns promises into policy or lets the opportunity slip away.
Trump and his handpicked healthcare leaders — HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary — have identified three major priorities: lowering drug prices, reversing chronic disease and unleashing generative AI. Each one, if achieved, would save tens of thousands of lives and reduce costs.
But promises are easy. Real change requires political will and congressional action. Here are three tests that Americans can use to gauge whether the Trump administration succeeds or fails in delivering on its healthcare agenda.
Americans pay two to four times more for prescription drugs than citizens in other wealthy nations. This price gap has persisted for more than 20 years and continues to widen as pharmaceutical companies launch new medications with average list prices exceeding $370,000 per year.
Today, nearly 30% of U.S. prescriptions go unfilled due to cost, leaving millions without the medications they need.
One key reason for the disparity is a 2003 law that prohibits Medicare from negotiating prices directly with drug manufacturers. Although the Inflation Reduction Act of 2022 granted limited negotiation rights, the initial round of price reductions did little to close the gap with other high-income nations.
President Trump has repeatedly promised to change that. In his first term, and again in May 2025, he condemned foreign 'free riders,' promising, 'The United States will no longer subsidize the healthcare of foreign countries and will no longer tolerate profiteering and price gouging.'
To support these commitments, the president signed an executive order titled 'Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients.' The order directs HHS to develop and communicate MFN price targets to pharmaceutical manufacturers, with the hope that they will voluntarily align U.S. drug prices with those in other developed nations. Should manufacturers fail to make significant progress toward these targets, the administration said it plans to pursue additional measures, such as facilitating drug importation and imposing tariffs. However, implementing these measures will most likely require congressional legislation and will encounter substantial legal and political challenges.
The pharmaceutical industry knows that without congressional action, there is no way for the president to force them to lower prices. And they are likely to continue to appeal to Americans by arguing that lower prices will restrict innovation and lifesaving drug development.
But the truth about drug 'innovation' is in the numbers: According to a study by America's Health Insurance Plans, seven out of 10 of the largest pharmaceutical companies spend more on sales and marketing than on research and development. And if drugmakers want to invest more in R&D, they can start by requiring peer nations to pay their fair share — rather than depending so heavily on U.S. patients to foot the bill.
If Congress fails to act, the president has other tools at his disposal. One effective step would be for the FDA to redefine 'drug shortages' to include medications priced beyond the reach of most Americans. That change would enable compounding pharmacies to produce lower-cost alternatives just as they did recently with GLP-1 weight-loss injections.
If no action is taken, however, and Americans continue paying more than twice as much as citizens in other wealthy nations, the administration will fail this crucial test.
Obesity has become a leading health threat in the United States, surpassing smoking and opioid addiction as a cause of death.
Since 1980, adult obesity rates have surged from 15% to over 40%, contributing significantly to chronic diseases, including type 2 diabetes, heart disease and multiple types of cancers.
A major driver of this epidemic is the widespread consumption of ultra-processed foods: products high in added sugar, unhealthy fats and artificial additives. These foods are engineered to be hyper-palatable and calorie-dense, promoting overconsumption and, in some cases, addictive eating behaviors.
RFK Jr. has publicly condemned artificial additives as 'poison' and spotlighted their impact on children's health. In May 2025, he led the release of the White House's Make America Healthy Again (MAHA) report, which identifies ultra-processed foods, chemical exposures, lack of exercise and excessive prescription drug use as primary contributors to America's chronic disease epidemic. But while the report raises valid concerns, it has yet to produce concrete reforms.
To move from rhetoric to results, the administration will need to implement tangible policies. Here are three approaches (from least difficult to most) that, if enacted, would signify meaningful progress:
These measures will doubtlessly face fierce opposition from the food and agriculture industries. But if the Trump administration and Congress manage to enact even one of these options — or an equivalent reform — they can claim success. If, instead, they preserve the status quo, leaving Americans to decipher nutritional fine print on the back of the box, obesity will continue to rise, and the administration will have failed.
The Trump administration has signaled a strong commitment to using generative AI across various industries, including healthcare. At the AI Action Summit in Paris, Vice President JD Vance made the administration's agenda clear: 'I'm not here this morning to talk about AI safety ... I'm here to talk about AI opportunity.'
FDA Commissioner Dr. Marty Makary has echoed that message with internal action. After an AI-assisted scientific review pilot program, he announced plans to integrate generative AI across all FDA centers by June 30.
But internal efficiency alone won't improve the nation's health. The real test is whether the administration will help develop and approve GenAI tools that expand clinical access, improve outcomes and reduce costs.
To these ends, generative AI holds enormous promise:
These breakthroughs aren't theoretical. They're achievable. But they won't happen unless federal leaders facilitate broad adoption.
That will require investing in innovation. The NIH must provide funding for next-generation GenAI tools designed for patient empowerment, and the FDA will need to facilitate approval for broad implementation. That will require modernizing current regulations. The FDA's approval process wasn't built for probabilistic AI models that rely on continuous application training and include patient-provided prompts. Americans need a new, fit-for-purpose framework that protects patients without paralyzing progress.
Most important, federal leaders must abandon the illusion of zero risk. If American healthcare were delivering superior clinical outcomes, managing chronic disease effectively and keeping patients safe, that would be one thing. But medical care in the United States is far from that reality. Hundreds of thousands of Americans die annually from poorly controlled chronic diseases, medical errors and misdiagnoses.
If generative AI technology remains confined to billing support and back-office automation, the opportunity to transform American healthcare will be lost. And the administration will have failed to deliver on this promise.
When I teach strategy at Stanford's Graduate School of Business, I tell students that the best leaders focus on a few high-priority goals with clear definitions of success — and a refusal to accept failure. Based on the administration's own words, grading the administration on these three healthcare tests will fulfill those criteria.
However, with Labor Day just months away, the window for action will soon close. The time for presidential action is now.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNET
17 minutes ago
- CNET
I Couldn't Fall Asleep Without Spiraling. These 5 Tricks Finally Helped
If your brain won't shut off at bedtime and you're stuck wide awake, spiraling through worst-case scenarios, you're not alone. Anxiety has a way of showing up right when you're trying to fall asleep, and there's a scientific reason for that. When your body senses stress, it releases cortisol, a hormone meant to keep you alert and ready for danger. Unfortunately, that also means you're left staring at the ceiling while your mind races. It's a frustrating cycle: Anxiety disrupts your sleep, and the lack of sleep makes your anxiety even worse the next day. But the good news is there are ways to break it. With a few simple strategies rooted in science and psychology, you can calm your nervous system and finally get the rest you need. If you're tired of tossing and turning, these expert-backed tips might be the key to falling and staying asleep. Want more? We've got more. Find out the sleep anxiety trick a CNET editor swears by, how to curb Sunday scaries and how to fall asleep when anxious. Read more: Best Mental Health Apps 1. Make your nighttime routine a ritual Not only does a routine help you relax enough to fall asleep, but it also helps combat stress and reduces symptoms of anxiety. Your nighttime routine will help keep you focused on relaxation and sleep. Everyone's routine is going to look different. Maybe yours includes light yoga or an hour of journaling to reflect on your day. Whatever it is, it's important to stick to your nightly routine when you find it -- do it at the same time and in the same order each night. Completing tasks in your nightly routine will signal to your brain that it's time to start winding down for sleep. Another mini tip within this tip: Don't lay in bed awake. If you climb into bed and find that you're not falling asleep, don't stay in bed. Instead, get up and do something relaxing, like read a book or take a bubble bath. The last thing you want to do is associate your bed with scrolling through social media or watching TV. 2. Don't drink too much I know this one can be a bit of a bummer, but what you eat and drink can affect your anxiety and how you sleep. Caffeine relates to anxiety and sleep in two ways. First, too much caffeine can exacerbate feelings of anxiety. The second is the obvious one; caffeine keeps you awake. As a rule, you should avoid drinking caffeine for 6 hours before you go to bed. Alcohol can also affect your anxiety symptoms and sleep by throwing off your circadian rhythm. Even if you find it easier to fall asleep after a few cocktails, many people wake up a few hours later when their body metabolizes the alcohol. Avoid drinking alcohol at least 4 hours before you go to sleep. 3. Use a meditation app Meditation apps are a quick and easy way to help yourself relax and fall asleep. Research shows that meditation can reduce stress and anxiety levels. It also reduces your blood pressure and heart rate. With the best meditation apps, you choose from guided meditations, deep breathing exercises or calming stories. There are a ton of options out there. Top meditation apps even have guided segments from celebrities like Harry Styles or Idris Elba.4. Add a weighted blanket to your bed Weighted blankets have been found to be an effective way to help calm anxiety and help you fall asleep, thanks to what's called deep-pressure stimulation. A 2020 study found that people who use a weighted blanket have lower rates of insomnia and anxiety. Using a weighted blanket isn't the only thing you should do, but it is an easy way to integrate comfort into your nightly routine. You can choose from the hundreds of options on the market or even make your own weighted blanket. Weighted blanket pro tip! Weighted blankets are a must if you live with anxiety. If you're in the market for one, try the Luna Weighted Blanket. We consider it the best overall weighted blanket because it's soft and breathable. Details $80 at Amazon 5. Acknowledge your anxiety All the tips in the world won't help you sleep easier with anxiety if you don't acknowledge you're feeling anxious. Whatever you're feeling -- stressed, scared or worried -- accept it so you can address it. It's a good idea to try to incorporate stress-relieving activities into your daily routine to help keep things from building up at night. Try a daily walk or other exercises to reduce anxiety. There's no set time frame for when you'll start falling asleep faster -- it likely won't be instantaneous. If you find that your anxiety is continually getting the best of your sleep, it may be time to talk to someone. The sleep advice doesn't end here. Also see the seven natural sleep aids for insomnia, which foods to eat to make you tired and why you should prioritize your sleep needs.


Forbes
17 minutes ago
- Forbes
IRS Should Treat Lawsuit Settlements For PTSD As Physical & Tax Free
Most lawsuit settlements are taxed, but there's an important exception: compensatory damages for personal physical injuries or physical sickness are tax free under Section 104 of the tax code. However, exactly what qualifies has been hotly debated for decades. Damages for emotional injuries are fully taxable, yet if you have emotional injuries triggered by physical ones, the damages for the emotional injuries are also tax-free. It can make taxing emotional distress and physical sickness a kind of chicken and egg issue. Settlement wording matters, as does the complaint. Adding to the confusion, exactly what is 'physical' is not defined. Traditionally, the IRS likes to see observable bodily harm such as bruises, cuts or broken bones. Yet many injuries are not obvious but can be worse and take longer to heal. What example, where do sexual abuse or sexual assault fit in? It may depend on how severe it is, what evidence you have, and more. For many victims, an award of cash comes with tax worries, can the IRS tax it? Allegations that a defendant caused a plaintiff to develop post-traumatic stress disorder occur in employment cases, wildfire and other disaster cases, personal injury claims, sexual harassment and abuse, defamation, and more. In some cases, the plaintiff claims the defendant caused their PTSD, and in others, that the defendant exacerbated pre-existing PTSD. Is an award for PTSD taxable or tax free as damages for personal physical injuries or physical sickness? There are good arguments that it is, including comments by President Obama about PTSD. However, there is no tax case yet that firmly decides one way or the other. The U.S. Tax Court upheld tax-free treatment where settlement monies are attributable to the exacerbation of a pre-existing physical condition. In one case, the Tax Court concluded that a portion of the plaintiff's settlement was excludable because it was attributable to damages flowing from a cardiac event attributable to emotional distress from an alleged employment-related tort, even though the plaintiff previously had the underlying heart condition. In another case, the Tax Court concluded that settlement monies from the employer were excludable because 'exposure to a hostile and stressful work environment exacerbated her MS symptoms to a point where she was unable to work.' PTSD can be caused or exacerbated by stress, but so can heart attacks and diseases, which are physical even when they are caused or worsened by stress. Cancer, lupus, multiple sclerosis, and many other diseases may also not be apparent, but those conditions are physical and can qualify for exclusion. There is a growing medical consensus that PTSD alters the taxpayer's brain physiology, and in a judgment or settlement, that ought to be sufficient to classify PTSD as physical injury or physical sickness. Fortunately, perhaps will finally feel some pressure on this issue. The National Structured Settlement Trade Association, NSSTA, is the leading representative of the structured settlement industry. They deserve applause for their recent Letter to the IRS that formally requests guidance from the IRS on this issue. Even without express IRS guidance, plaintiffs and defendants are increasingly likely to be able to agree on these issues. In settlement agreements, it is becoming common for defendants to agree that PTSD is physical injury or sickness for tax purposes. But without a published tax case that expressly states that PTSD damages qualify for exclusion, some defendants will not agree. That leaves some plaintiffs out in the cold. In any case, settlement agreement wording does not bind the IRS. A tax opinion is wise and helps protect the plaintiff, but even this is not a guarantee.


Medscape
17 minutes ago
- Medscape
Novel Gene Risk Score Predicts Outcomes After RYGB Surgery
A novel gene risk score, informed by machine learning, predicted weight-loss outcomes after Roux-en-Y gastric bypass (RYGB) surgery, a new analysis showed. The findings suggested that the MyPhenome test (Phenomix Sciences) can help clinicians identify the patients most likely to benefit from bariatric procedures and at a greater risk for long-term weight regain after surgery. 'Patients with both a high genetic risk score and rare mutations in the leptin-melanocortin pathway (LMP) had significantly worse outcomes, maintaining only 4.9% total body weight loss [TBWL] over 15 years compared to up to 24.8% in other genetic groups,' Phenomix Sciences Co-founder Andres Acosta, MD, PhD, told Medscape Medical News . The study included details on the score's development and predictive capability. 'More Precise Bariatric Care' The researchers recently developed a machine learning-assisted gene risk score for calories to satiation (CTSGRS), which mainly involves genes in the LMP. To assess the role of the score with or without LMP gene variants on weight loss and weight recurrence after RYGB, they identified 707 patients with a history of bariatric procedures from the Mayo Clinic Biobank. Patients with duodenal switch, revisional procedures, or who used antiobesity medications or became pregnant during follow-up were excluded. To make predictions for 442 of the patients, the team first collected anthropometric data up to 15 years after RYGB. Then they used a two-step approach: Assessing for monogenic variants in the LMP and defining participants as carriers (LMP+) or noncarriers (LMP-). Then they defined the gene risk score (CTSGRS+ or CTSGRS-). The result was four groups: LMP+/CTSGRS+, LMP+/CTSGRS-, LMP-/CTSGRS+, and LMP-/CTSGRS-. Multiple regression analysis was used to analyze TBWL percentage (TBWL%) between the groups at different timepoints, adjusting for baseline weight, age, and gender. At the 10-year follow-up, the LMP+/CTSGRS+ group demonstrated a significantly higher weight recurrence (regain) of TBW% compared to the other groups. At 15 years post-RYGB, the mean TBWL% for LMP+/CTSGRS+ was -4.9 vs -20.3 for LMP+/CTSGRS-, -18.0 for LMP-/CTSGRS+, and -24.8 for LMP-/CTSGRS-. Further analyses showed that the LMP+/CTSGRS+ group had significantly less weight loss than LMP+/CTSGRS- and LMP-/CTSGRS- groups. Based on the findings, the authors wrote, 'Genotyping patients could improve the implementation of individualized weight-loss interventions, enhance weight-loss outcomes, and/or may explain one of the etiological factors associated with weight recurrence after RYGB.' Acosta noted, 'We're actively expanding our research to include more diverse populations by age, sex, and race. This includes ongoing analysis to understand whether certain demographic or physiological characteristics affect how the test performs, particularly in the context of bariatric surgery.' The team also is investigating the benefits of phenotyping for obesity comorbidities such as heart disease and diabetes, he said, and exploring whether early interventions in high-risk patients can prevent long-term weight regain and improve outcomes. In addition, Acosta said, the team recently launched 'the first prospective, placebo-controlled clinical trial using the MyPhenome test to predict response to semaglutide.' That study is based on earlier findings showing that patients identified with a Hungry Gut phenotype lost nearly twice as much weight on semaglutide compared with those who tested negative. Overall, he concluded, 'These findings open the door to more precise bariatric care. When we understand a patient's biological drivers of obesity, we can make better decisions about the right procedure, follow-up, and long-term support. This moves us away from a one-size-fits-all model to care rooted in each patient's unique biology.' Potentially Paradigm-Shifting Onur Kutlu, MD, associate professor of surgery and director of the Metabolic Surgery and Metabolic Health Program at the Miller School of Medicine, University of Miami, Miami, commented on the study for Medscape Medical News . 'By integrating polygenic risk scores into predictive models, the authors offer an innovative method for identifying patients at elevated risk for weight regain following RYGB.' 'Their findings support the hypothesis that genetic predisposition — particularly involving energy homeostasis pathways — may underlie differential postoperative trajectories,' he said. 'This approach has the potential to shift the paradigm from reactive to proactive management of weight recurrence.' Because current options for treat weight regain are 'suboptimal,' he said, 'prevention becomes paramount. Preoperative identification of high-risk individuals could inform surgical decision-making, enable earlier interventions, and facilitate personalized postoperative monitoring and support.' 'If validated in larger, prospective cohorts, genetic risk stratification could enhance the precision of bariatric care and improve long-term outcomes,' he added. 'Future studies should aim to validate these genetic models across diverse populations and explore how integration of behavioral, psychological, and genetic data may further refine patient selection and care pathways.' The study presented at Digestive Disease Week (DDW) 2025 was funded by Mayo Clinic and Phenomix Sciences. Gila Therapeutics and Phenomix Sciences licensed Acosta's research technologies from the University of Florida and Mayo Clinic. Acosta declared receiving consultant fees in the past 5 years from Rhythm Pharmaceuticals, Gila Therapeutics, Amgen, General Mills, BI, Currax, Nestle, Phenomix Sciences, Bausch Health, and RareDiseases, as well as funding support from the National Institutes of Health, Vivus Pharmaceuticals, Novo Nordisk, Apollo Endosurgery, Satiogen Pharmaceuticals, Spatz Medical, and Rhythm Pharmaceuticals. Kutlu declared having no conflicts of interest.